CLINICAL TRIALS PROFILE FOR IBANDRONATE SODIUM

All Clinical Trials for ibandronate sodium

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00082927 ↗	Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain	Completed	Cancer Research UK	Phase 3	2003-04-01	RATIONALE: Ibandronate may be effective in reducing bone pain caused by metastatic cancer. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether ibandronate is more effective than standard treatment with radiation therapy in treating metastatic bone pain. PURPOSE: This phase III randomized clinical trial is studying ibandronate to see how well it works compared to single-dose local radiation therapy in treating patients with localized metastatic bone pain.
NCT00127205 ↗	S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.	Completed	Cancer and Leukemia Group B	Phase 3	2005-07-01	RATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in patients with nonmetastatic breast cancer. It is not yet known whether zoledronate is more effective than clodronate or ibandronate in treating breast cancer. PURPOSE: This randomized phase III trial is studying zoledronate to see how well it works compared to clodronate or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
NCT00127205 ↗	S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.	Completed	Eastern Cooperative Oncology Group	Phase 3	2005-07-01	RATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in patients with nonmetastatic breast cancer. It is not yet known whether zoledronate is more effective than clodronate or ibandronate in treating breast cancer. PURPOSE: This randomized phase III trial is studying zoledronate to see how well it works compared to clodronate or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.

Clinical Trial Conditions for ibandronate sodium

Condition Name

Condition Name for ibandronate sodium
Intervention	Trials
Breast Cancer	4
Metastatic Cancer	3
Pain	2

Condition MeSH

Condition MeSH for ibandronate sodium
Intervention	Trials
Breast Neoplasms	4
Neoplasm Metastasis	3
Paraneoplastic Syndromes	2

Clinical Trial Locations for ibandronate sodium

Trials by Country

Trials by Country for ibandronate sodium
Location	Trials
United States	23
United Kingdom	7
India	1

Trials by US State

Trials by US State for ibandronate sodium
Location	Trials
Pennsylvania	2
New York	2
New Mexico	2
Michigan	2
Maryland	2

Clinical Trial Progress for ibandronate sodium

Clinical Trial Phase

Clinical Trial Phase for ibandronate sodium
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	4
Phase 1	1

Clinical Trial Status

Clinical Trial Status for ibandronate sodium
Clinical Trial Phase	Trials
Completed	5
Withdrawn	2
Unknown status	1

Clinical Trial Sponsors for ibandronate sodium

Sponsor Name

Sponsor Name for ibandronate sodium
Sponsor	Trials
National Cancer Institute (NCI)	3
Southwest Oncology Group	3
Dr. Reddy's Laboratories Limited	1

Sponsor Type

Sponsor Type for ibandronate sodium
Sponsor	Trials
Other	11
NIH	3
Industry	3

Ibandronate sodium Market Analysis and Financial Projection

Last updated: April 27, 2026

Ibandronate Sodium: Clinical Trials Update, Market Analysis, and Projection

What is ibandronate sodium and what is its clinical role?

Ibandronate sodium is a bisphosphonate used to reduce skeletal-related events in postmenopausal osteoporosis and to treat bone metastases from breast cancer with an aim to lower risk of skeletal events. Commercially, the core branded formulations are typically delivered as:

• Oral: ibandronate tablets (commonly 2.5 mg once daily or 150 mg once monthly, depending on jurisdiction/product)
• Intravenous (IV): ibandronate injection (commonly 3 mg every 3 months in many markets)

What is the current clinical-trials landscape?

No current, verifiable global “clinical trials update” can be produced from the information available in this prompt. A complete and accurate update requires a date-stamped scan of registries (e.g., ClinicalTrials.gov, EU CTR, WHO ICTRP) with trial status, identifiers, and endpoints, then mapping those to ibandronate sodium and its specific formulations (oral vs IV) and dosing regimens. With only the drug name provided, a precise update would risk omission or misattribution.

Accordingly, this section is not provided.

---

How does the market for ibandronate sodium look today?

What are the commercial demand drivers?

Ibandronate sodium demand is driven by:

• Osteoporosis prevalence in postmenopausal populations and guideline-directed long-term fracture risk reduction
• Adoption of antiresorptive regimens that offer adherence advantages (e.g., monthly dosing or 3-monthly IV schedules in markets where used)
• Cancer supportive care use in breast cancer bone metastases where it is positioned among IV bisphosphonates

Where does competitive pressure typically come from?

In osteoporosis and cancer bone-supportive care, ibandronate competes against:

• Other bisphosphonates (oral and IV)
• Denosumab (RANKL inhibitor)
• Sclerostin pathway agents (e.g., romosozumab where reimbursed)
• For oncology bone events, regimens built around denosumab and other approved standards

What is the market structure by segment?

For business planning, ibandronate sodium market exposure typically breaks into two channels:

1. Osteoporosis (postmenopausal)
2. Oncology supportive care (bone metastases in breast cancer)

Because the prompt contains no sales figures, pricing, patent status, or geography, a numeric market assessment cannot be completed without pulling and reconciling external sources (payer, sales databases, filings, and label-market mapping).

Accordingly, this section is not provided.

---

What market projections can be made for ibandronate sodium?

A credible projection requires:

• Baseline market size by geography and segment
• Expected label life and competitive horizon (loss of exclusivity, biosimilar/better-cheaper shifts, formulary dynamics)
• Expected treatment migration between osteoporosis agents and supportive care agents
• Forecast assumptions tied to registry of administered dosing schedules and reimbursement controls

The prompt does not provide any of these inputs, and numeric forecasting without a sourced baseline would not meet an “actionable insights” standard.

Accordingly, this section is not provided.

---

Key Takeaways

• Ibandronate sodium is used in postmenopausal osteoporosis and bone metastases from breast cancer, typically via oral and IV (interval-based) dosing regimens.
• A complete clinical trials update and market analysis/projection requires registry- and market-grade inputs that are not present in the prompt.
• No registry-verified trial status update, no quantified market sizing, and no projection figures are provided.

---

FAQs

Is ibandronate sodium still used in osteoporosis treatment today?

Yes. It remains an antiresorptive bisphosphonate option in postmenopausal osteoporosis care in jurisdictions where it is available and reimbursed under label and local guideline criteria.

What are the main formulations for ibandronate sodium?

It is typically marketed as both an oral product (commonly daily or monthly dosing depending on brand/jurisdiction) and an IV injection with longer interval dosing (often quarterly in many markets).

Does ibandronate sodium have an oncology indication?

Yes. It is used for skeletal-related event risk reduction in bone metastases from breast cancer in the approved settings of the product label.

Which competitors most often impact ibandronate share?

In osteoporosis and oncology bone supportive care, competition often comes from other bisphosphonates and from denosumab and other classes where guidelines and reimbursement favor them.

Can you provide a sourced trials and market forecast from only the drug name?

No. A trials update requires registry identifiers and dates, and market projections require baseline sales, geography, and competitive/policy assumptions.